Recombinant Mouse Stimulator of interferon genes protein (Sting1)

What is the fundamental role of STING1 in mouse immune responses?

STING1 functions as a major regulator of the innate immune response to viral and bacterial infections. The protein is encoded by the Sting1 gene and operates as a pattern recognition receptor that detects cytosolic nucleic acids, subsequently transmitting signals that activate type I interferon responses. These interferon responses are critical for establishing antiviral states in cells . STING1 is a five-transmembrane protein that, upon binding of cyclic dinucleotides like c-di-GMP or cGAMP, undergoes oligomerization and translocation from the endoplasmic reticulum. TBK1 then phosphorylates STING1 on the pLxIS motif, leading to recruitment and activation of the transcription factor IRF3, which induces type I interferon expression . Beyond interferon production, STING1 also plays a direct role in autophagy processes, making it a multifunctional protein in immune regulation .

How do mouse models help elucidate human STING1 variant functions?

Mouse models with knock-ins of human STING1 variants provide valuable experimental systems for studying how these variants function in an in vivo context. Researchers have generated mice expressing common human STING1 alleles such as HAQ (R71H-G230A-R293Q), AQ (G230A-R293Q), and Q293, which are carried by significant portions of human populations—approximately 60% of East Asians carry HAQ alleles and about 40% of Africans carry AQ alleles . These mouse models allow researchers to investigate how these common alleles modulate immune responses and inflammatory conditions like STING-associated vasculopathy with onset in infancy (SAVI) . By comparing wild-type mice with those expressing human STING1 variants, researchers can identify critical residues and mechanisms involved in STING1 function. For example, studies using these models have established the crucial role of residue 293 in STING1-mediated cell death .

What are the key experimental considerations when working with recombinant mouse STING1?

When working with recombinant mouse STING1, several methodological considerations are essential:

Proper controls and validation experiments are necessary to ensure reproducibility and relevance of results when working with recombinant STING1 protein .

How do common human STING1 alleles (HAQ, AQ, Q293) affect cell death mechanisms in experimental systems?

Research using knock-in mice expressing human STING1 variants has revealed that HAQ, AQ, and Q293 alleles significantly alter STING1-mediated cell death. The residue 293 of STING1 plays a critical role in this process, as splenocytes from mice expressing these variants show resistance to STING1-mediated cell death ex vivo .

Mechanistically, STING1-mediated cell death appears to be independent of type I interferons, which is particularly important for understanding therapeutic implications . Studies have demonstrated that WT/HAQ and WT/AQ heterozygous splenocytes are protected from cell death induced by 25 μg/ml of the STING1 agonist DMXAA, though higher concentrations (100 μg/ml) can still induce cell death, albeit less effectively than in WT/WT cells . This indicates that the HAQ and AQ alleles have a dominant effect and can impact STING1 activation even in heterozygosity.

Similarly, human primary cells from individuals with the WT/HAQ genotype show resistance to low-dose diABZI-induced cell death compared to WT/WT cells . These findings establish a critical molecular basis for understanding how common genetic variants influence STING1 function in diverse human populations.

What methodological approaches can distinguish between different cell death pathways activated by STING1?

Distinguishing between the multiple cell death pathways potentially activated by STING1 requires comprehensive methodological approaches:

• Pathway-specific inhibitors: Researchers should employ specific inhibitors of apoptosis (e.g., Z-VAD-FMK), necroptosis (e.g., necrostatin-1), pyroptosis (e.g., VX-765), and ferroptosis (e.g., ferrostatin-1) to identify the predominant mechanism in their experimental system .

• Genetic approaches: Utilize knockout or knockdown of key molecules in each death pathway (e.g., caspases for apoptosis, MLKL for necroptosis) to confirm pathway involvement.

• Cell type consideration: STING1-mediated cell death manifests differently depending on cell type. While STING1 activation kills human endothelial cells and T cells, it does not kill mouse MEFs, BMDCs, or BMDMs . Human studies show that diABZI and RpRpss-Cyclic di-AMP kill human CD4 T cells but not CD8 T or CD19 B cells .

• Species-specific variations: Researchers must account for differences between mouse and human systems, as the mechanisms and susceptibility to STING1-mediated death vary between species .

• Morphological and biochemical assessment: Combine flow cytometry, microscopy, and biochemical assays to characterize cell death features and molecular markers specific to each pathway.

The complexity observed in STING1-mediated cell death likely stems from the variation in experimental systems, including different cell types and STING1 agonists used in studies .

How can researchers interpret CD4 T cellpenia in STING1-related disease models?

CD4 T cellpenia (reduced CD4 T cell numbers) is a significant feature observed in both SAVI patients and mouse models. Interpreting this phenomenon requires careful experimental design and analysis:

• Phenotypic characterization: Comprehensive immunophenotyping should be performed, analyzing not just CD4 T cell numbers but also their subsets, particularly regulatory T cells (Tregs). Research has shown that HAQ/SAVI(N153S) and AQ/SAVI(N153S) mice have significantly more Tregs (~10-fold and ~20-fold, respectively) than WT/SAVI(N153S) mice .

• Mechanistic evaluation: CD4 T cellpenia mechanisms should be assessed through both in vitro cell death assays and in vivo adoptive transfer studies. STING1 activation has been shown to kill CD4 T cells ex vivo, but the in vivo significance was unclear until studies with SAVI mice .

• Comparative analysis: Researchers should compare findings between different STING1 genotypes. The HAQ/SAVI(N153S) and AQ/SAVI(N153S) mice do not develop CD4 T cellpenia, suggesting that these common alleles can rescue the SAVI phenotype .

• Translational relevance: Interestingly, while SAVI mouse models show both CD4 and CD8 T cellpenia, human SAVI patients typically have normal CD8+ T cell numbers but reduced CD4+ T cells . Addressing this discrepancy is critical for understanding the translational relevance of mouse models.

Based on these studies, researchers have proposed that STING1 activation promotes tissue inflammation by depleting Tregs in vivo, providing a potential mechanism for SAVI pathogenesis and suggesting new therapeutic targets .

What are the key differences between mouse and human STING1 function that impact experimental design?

Significant differences exist between mouse and human STING1 function that researchers must consider:

These differences explain why STING1 research has faced challenges in clinical translation. Researchers should consider using human STING1 knock-in mice (especially with common alleles like HAQ and AQ) to better model human responses . Additionally, validating findings in primary human cells is essential before making translational claims.

What experimental approaches are most effective for studying STING1 activation in T cell regulation?

Studying STING1 activation in T cell regulation requires specialized experimental approaches:

• Knock-in mouse models: Utilize mice expressing human STING1 variants (HAQ, AQ, Q293) to study allele-specific effects. These models have revealed that HAQ/SAVI(N153S) and AQ/SAVI(N153S) mice have more Tregs than WT/SAVI(N153S) mice, suggesting allele-specific effects on T cell regulation .

• Ex vivo cell death assays: Treat splenocytes or human primary cells with STING1 agonists (2'3'-cGAMP, RpRpss-Cyclic di-AMP, diABZI) and measure cell death by Propidium Iodide staining to assess STING1-mediated cell death in different T cell subsets .

• Cell type-specific analysis: Separate analysis of CD4 T, CD8 T, and CD19 B cells is crucial as STING1-mediated effects are highly cell type-dependent. For instance, diABZI and RpRpss-Cyclic di-AMP kill human CD4 T but not CD8 T or CD19 B cells .

• Dose titration: Carefully titrate STING1 agonists as different doses can yield varying results. WT/HAQ and WT/AQ splenocytes resist 25 μg/ml DMXAA-induced cell death but succumb to 100 μg/ml DMXAA .

• Regulatory T cell assessment: Quantify Treg numbers and function in different STING1 genotypes, as the HAQ/SAVI(N153S) and AQ/SAVI(N153S) mice have significantly more Tregs than WT/SAVI(N153S) mice, which may explain their protection from inflammatory disease .

These approaches have led to the hypothesis that STING1 activation promotes tissue inflammation by depleting Tregs in vivo, which could guide future therapeutic strategies targeting the STING1 pathway .

How should STING1 allelic variation inform therapeutic applications and clinical trial design?

STING1 allelic variation has significant implications for therapeutic applications and clinical trial design:

• Genotype-stratified trials: Clinical trials should stratify participants based on STING1 genotype (WT/WT, WT/HAQ, WT/AQ, etc.), as these variations significantly impact STING1 function. The HAQ allele is carried by approximately 60% of East Asians, while the AQ allele is present in about 40% of Africans .

• Personalized dosing: WT/HAQ and WT/AQ individuals may require different dosing of STING1-targeting therapeutics. Ex vivo studies show that WT/HAQ and WT/AQ splenocytes resist low-dose but not high-dose STING1 agonists .

• Efficacy predictions: The disappointing results from STING1 agonist-based clinical trials (NCT02675439, NCT03010176, NCT05514717) may be partly explained by inadequate consideration of participant STING1 genotypes .

• Safety monitoring: Different STING1 alleles may influence the safety profile of STING1-targeting therapeutics. The AQ/SAVI mice show no tissue inflammation, regular body weight, and normal lifespan despite having comparable TBK1, IRF3, and NFκB activation as WT/SAVI mice .

• Population-specific expectations: Therapeutic outcomes may vary among different populations due to the uneven distribution of STING1 alleles across human populations. Clinical trial design and analysis should account for these demographic differences .

The evidence strongly suggests that STING1 heterogeneity in humans should be a key consideration in both research and clinical applications of STING1-targeting immunotherapies .

What are the key considerations when developing experimental models for STING-associated vasculopathy (SAVI)?

Developing effective experimental models for STING-associated vasculopathy (SAVI) requires attention to several critical factors:

These models have already provided valuable insights, suggesting that STING1 activation promotes tissue inflammation by depleting T-regulatory cells in vivo, which may guide the development of new therapeutic approaches .

What techniques are most effective for detecting and measuring STING1 activation in experimental systems?

Effective detection and measurement of STING1 activation requires multiple complementary approaches:

• Phosphorylation analysis: Monitor phosphorylation of TBK1 and IRF3, which are key downstream events following STING1 activation. Western blotting with phospho-specific antibodies can quantify these events .

• Translocation assays: Track STING1 translocation from the endoplasmic reticulum following activation using immunofluorescence microscopy or subcellular fractionation techniques .

• Interferon production: Measure type I interferon production using ELISA, qPCR, or reporter assays as a functional readout of STING1 activation .

• Oligomerization detection: Assess STING1 oligomerization following ligand binding using native PAGE, crosslinking studies, or FRET-based approaches .

• Cell death assessment: Quantify cell death as a STING1 activation outcome using flow cytometry with viability dyes such as Propidium Iodide staining. This is particularly relevant for studying STING1-mediated CD4 T cell death .

• Pathway activation markers: Examine activation of NFκB pathway components alongside TBK1/IRF3 to get a complete picture of STING1 signaling outputs .

It's important to note that STING1-mediated cell death is independent of type I IFN production, so researchers should not rely solely on interferon readouts to assess STING1 function . Additionally, experimental readouts may vary depending on the cell type being studied, as STING1 effects are highly cell type-dependent .

How can researchers optimize experimental conditions for studying STING1-mediated cell death?

Optimizing experimental conditions for studying STING1-mediated cell death requires careful attention to multiple variables:

It's crucial to include appropriate controls, such as cells from animals with different STING1 genotypes (e.g., WT/WT, WT/HAQ, WT/AQ) to understand the impact of genetic variation . Additionally, researchers should consider validating key findings in both mouse and human systems, as there are important species differences in STING1 function .

What are the most reliable protocols for generating and validating STING1 knock-in mouse models?

Generating and validating STING1 knock-in mouse models requires rigorous protocols to ensure model fidelity and research reproducibility:

• Targeting vector design:

  • Include the desired mutation in the mouse Sting1 gene or introduce the human STING1 variant

  • Incorporate selection markers (e.g., neo gene) flanked by recombination sites (e.g., FRT)

  • Include sufficient homology arms for efficient recombination

• Embryonic stem cell targeting:

  • Transfect linearized targeting vector into C57BL/6N embryonic stem cells

  • Select positive clones using appropriate antibiotics

  • Verify correct targeting by PCR and sequencing

• Chimera generation:

  • Inject targeted ES cells into C57BL/6J blastocysts

  • Transfer to pseudopregnant females

  • Identify chimeric offspring by coat color

• Germline transmission verification:

  • Breed chimeric mice to confirm germline transmission

  • Use PCR sequencing to confirm the presence of the desired mutation

• Selection marker removal:

  • Breed heterozygous mice to transgenic mice expressing appropriate recombinase (e.g., Actin-flpase mice to remove neo gene using FRT sites)

  • Verify marker removal by PCR

• Validation procedures:

  • Confirm expression of the mutant protein by Western blotting

  • Verify functional changes using ex vivo assays (e.g., STING1 agonist-induced cell death in splenocytes)

  • Characterize phenotypic features relevant to the research question (e.g., CD4 T cell numbers in SAVI models)

• Experimental controls:

  • Use age- and gender-matched mice (2-6 months old, both male and female)

  • Randomly assign littermates of the same sex to experimental groups

  • Perform treatments blindly where possible to prevent bias

These protocols have been successfully used to generate HAQ, AQ, and Q293 knock-in mice, which have provided valuable insights into STING1 function and its role in inflammatory diseases .

What are the emerging research questions regarding STING1 function in autoimmunity and cancer immunotherapy?

The field of STING1 research is evolving rapidly, with several key emerging questions:

• Allele-specific therapeutic responses: How do common STING1 alleles (HAQ, AQ) influence responses to STING1-targeting cancer immunotherapies? The disappointing results from clinical trials may be partly explained by inadequate consideration of participant STING1 genotypes .

• Regulatory T cell mechanisms: What is the precise mechanism by which STING1 activation depletes regulatory T cells in vivo? Understanding this process could provide new therapeutic targets for both autoimmune conditions and cancer .

• Cell death pathway determination: Which of the multiple proposed cell death mechanisms (apoptosis, necroptosis, pyroptosis, ferroptosis, PANoptosis) is most relevant in different pathological contexts? This remains unclear despite extensive research .

• Species-specific differences: How can we better account for the differences between mouse and human STING1 function to improve translational research? The poor transferability of mouse findings to humans has been a significant issue .

• Personalized medicine applications: How should STING1 genotyping be incorporated into clinical decision-making for inflammatory diseases and cancer immunotherapy? Billions of humans carry the dominant HAQ and AQ alleles, which could significantly impact treatment outcomes .

• Non-canonical functions: Beyond interferon induction and cell death, what other cellular processes does STING1 regulate? Research has already identified roles in autophagy, but additional functions may exist .

These questions highlight the importance of considering STING1 heterogeneity in humans for both research and clinical applications of STING1-targeting therapeutics .

How might tissue-specific STING1 functions inform therapeutic development strategies?

Understanding tissue-specific STING1 functions is crucial for developing targeted therapeutic strategies:

• T cell compartment: STING1 activation differentially affects CD4 vs. CD8 T cells, with CD4 T cells being more susceptible to STING1-mediated cell death in humans. Therapeutic approaches may need to account for these differences, particularly in conditions where T cell preservation is desired .

• Regulatory T cell preservation: HAQ/SAVI(N153S) and AQ/SAVI(N153S) mice have significantly more Tregs than WT/SAVI(N153S) mice. This suggests that modulating STING1 activity to preserve Tregs could be beneficial in inflammatory conditions .

• Cell type-specific targeting: STING1 activation kills human endothelial cells and T cells but not mouse MEFs, BMDCs, or BMDMs. Developing delivery systems that target specific cell populations could enhance therapeutic efficacy while reducing off-target effects .

• Tissue microenvironment considerations: Local tissue factors may influence STING1 signaling outcomes. Studies comparing different tissues may reveal important context-dependent effects that could be therapeutically relevant .

• Genetic background integration: Therapeutic development should consider how different STING1 alleles function in specific tissues. The WT/HAQ genotype is the most common in East Asians (~34.3%), while WT/AQ is the second most common in Africans (~28.2%), suggesting population-specific therapeutic considerations .